Teleflex

TFX

Market cap $5.76B

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has published its 2025 Global Impact Report. The report outlines recent accomplishments and future plans to support the Company's Corporate Social Responsibility (CSR) program. The report aligns with the Global Reporting Initiative (GRI), the Sustainability Accounting Standards Board (SASB), and Taskforce on Climate-Related Financial Disclosures (TCFD). “This yea.

Investors need to pay close attention to TFX stock based on the movements in the options market lately.

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the beginning of enrollment in the BIOMAG™‑III Study (NCT07258290), a landmark global study evaluating the Freesolve™ Resorbable Magnesium Scaffold (RMS). Dr. Itsik Ben-Dor, MedStar Health in Washington, D.C., is the first implanter in the United States (U.S.) in the IDE trial of Freesolve™ RMS. Designed as a pivotal trial to support future regulatory applications,.

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the four‑year follow‑up data from the First-in-Human BIOMAG™-I Clinical Study (NCT04157153)* presented at the EuroPCR conference in Paris, France by Prof. Jan Torzewski (Klinikverbund Allgäu, Germany). Conducted exclusively across European centers and enrolling 116 patients, the study continues to demonstrate a favorable long‑term safety profile1, with no new cardia.

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) (“Teleflex”) announced today that it priced its private offering of $500.0 million aggregate principal amount of 5.875% senior notes due 2032 (the “Notes”) at an issue price of 100.000%. The sale of the Notes is expected to close on June 15, 2026, subject to customary closing conditions. The Notes will be guaranteed by each of Teleflex's existing and future wholly-owned domestic subsidiaries that is a guarantor or other obligor unde.

Teleflex's portfolio reset is pressuring results, but a cheaper valuation and divestiture proceeds could reshape its outlook over the next 6-12 months.

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) (“Teleflex”) announced today the commencement of a private offering of $500.0 million aggregate principal amount of senior notes due 2032 (the “Notes”), subject to market and other conditions. The interest rate and other terms of the Notes will be determined at pricing. The Notes will be guaranteed by each of Teleflex's existing and future wholly-owned domestic subsidiaries that is a guarantor or other obligor under its credit agree.

TFX targets $2.03B in divestiture proceeds; FTC review, tariffs and remediation costs put 2026 timing, margins and leverage in play.

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the Interventional Urology Business Unit has released new clinical data across two major urological congresses, reinforcing the value of the UroLift™ System and Barrigel™ rectal spacer in improving patient-centered outcomes across benign prostatic hyperplasia (BPH) and prostate cancer care. Teleflex Interventional Urology innovations help urologists treat medical ne.

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable June 30, 2026, to shareholders of record at the close of business on May 25, 2026. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the.